- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02929030
Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease
December 29, 2016 updated by: Tao Ling, Xijing Hospital
Safety and Efficacy of Polymer-free Sirolimus-eluting Coronary Stents in Patients With Coronary Artery Disease.
The study aims to evaluate the safety and efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with coronary artery disease .
The primary endpoint is target lesion failure, a composite endpoint of cardiac death, target vessel related myocardial infarction and clinically-driven target lesion revascularization at 1 year follow-up.
Study Overview
Detailed Description
This is a prospective, multicenter, single arm clinical registry investigating the safety and efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with coronary artery disease .
In total, we plan to recruit 2500 patients in real world setting.
The patients will be followed clinically at 1-, 6- month and 1-, 2-, 3-, 4-, 5-year.
All clinical data will be collected and managed by statistical center, clinical endpoint adjudication committee.
Study Type
Observational
Enrollment (Anticipated)
2500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanxi
-
Xi'an, Shanxi, China
- Recruiting
- Xijing Hospital
-
Contact:
- Chen Wang
- Phone Number: 15802929290
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with coronary artery disease
Description
Inclusion Criteria:
- 18-85 years old, male or non-pregnancy female;
- Patients with coronary artery disease who match the indication of stent implantation;
- Patients who can understand the nature of the study, agree to participate and accept clinical follow-up;
Exclusion Criteria:
- Patients who can not tolerate the material or medication in this study;
- Pregnancy or lactation women
- Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
- Patients are, in the opinion of the investigator, unable to comply with the requirements of the study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
NANO Plus SES
All patients will be treated with NANO plus sirolimus-eluting stent.
Patients will be prescribed with clopidogrel and aspirin before the index procedure.
The lesions will be predilted if necessary before stent implantation.
There are no specific limitations on coronary lesions according the study criteria.
|
The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
target lesion failure (TLF)
Time Frame: 12 months
|
cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Target lesion failure
Time Frame: 1、6、12、24、36、48、60 months
|
a composite endpoint of cardiac death, target lesion related myocardial infarction, and/or target lesion revascularization
|
1、6、12、24、36、48、60 months
|
|
Patient oriented composite endpoint
Time Frame: 1、6、12、24、36、48、60 months
|
a composite endpoint of all cause death, all myocardial infarction and all revascularization
|
1、6、12、24、36、48、60 months
|
|
all cause death
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
cardiac death
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Myocardial infarction
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Stent thrombosis
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Target lesion revascularization
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
Target vessel revascularization
Time Frame: 1、6、12、24、36、48、60 months
|
1、6、12、24、36、48、60 months
|
|
|
target lesion failure
Time Frame: 1、6、24、36、48、60 months
|
cardiac death, target vessel related myocardial infarction and/or clinically driven target lesion revascularization
|
1、6、24、36、48、60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Yao-Jun Zhang, PhD, Nanjing First Hospital, Nanjing Medical University
- Principal Investigator: Lin Tao, PhD, Xijing Hospital
- Principal Investigator: Yue Li, PhD, The First Clinical Hospital affiliated to Harbin Medical University
- Principal Investigator: Zhiqi Sun, PhD, Daqing oilfield central hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Suwannasom P, Onuma Y, Benit E, Gach O, von Birgelen C, Hofma SH, Sotomi Y, Bo X, Zhang YJ, Gao R, Garcia-Garcia HM, Wykrzykowska JJ, de Winter RJ, Serruys PW. Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. EuroIntervention. 2016 Aug 5;12(5):e574-83. doi: 10.4244/EIJV12I5A97.
- Zhang Y, Chen F, Muramatsu T, Xu B, Li Z, Ge J, He Q, Yang Z, Li S, Wang L, Wang H, He B, Li K, Qi G, Li T, Zeng H, Peng J, Jiang T, Zeng Q, Zhu J, Fu G, Bourantas CV, Serruys PW, Huo Y. Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial. Chin Med J (Engl). 2014;127(11):2153-8.
- Dai Y, Wang R, Chen F, Zhang Y, Liu Y, Huang H, Yang P, Zhang R, Zheng B, Gao C, Chen Y, Tao L. Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry. BMC Cardiovasc Disord. 2021 Nov 12;21(1):537. doi: 10.1186/s12872-021-02356-0.
- Liu Y, Zhang Y, Li Y, Qi T, Pan D, Wang H, Liu C, Ma D, Fang Z, Zhang R, Mou F, Tao L; NANO All-Comers Registry Investigators. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent. Catheter Cardiovasc Interv. 2020 Feb;95 Suppl 1:658-664. doi: 10.1002/ccd.28734. Epub 2020 Jan 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Anticipated)
January 1, 2018
Study Completion (Anticipated)
January 1, 2022
Study Registration Dates
First Submitted
October 6, 2016
First Submitted That Met QC Criteria
October 6, 2016
First Posted (Estimate)
October 10, 2016
Study Record Updates
Last Update Posted (Estimate)
December 30, 2016
Last Update Submitted That Met QC Criteria
December 29, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NANOxijing001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.